Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
History of invasive and interventional cardiology wikipedia , lookup
Saturated fat and cardiovascular disease wikipedia , lookup
Quantium Medical Cardiac Output wikipedia , lookup
Jatene procedure wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Journal of the American College of Cardiology © 2007 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 49, No. 5, 2007 ISSN 0735-1097/07/$32.00 doi:10.1016/j.jacc.2006.09.040 Relationship Between C-Reactive Protein Levels and Regional Left Ventricular Function in Asymptomatic Individuals The Multi-Ethnic Study of Atherosclerosis Boaz D. Rosen, MD,* Mary Cushman, MD,† Khurram Nasir, MD, MPH,* David A. Bluemke, MD, PHD,‡ Thor Edvardsen, MD, PHD,* Verônica Fernandes, MD, PHD,* Shenghan Lai, MD, PHD,§ Russell P. Tracy, PHD,† João A. C. Lima, MD, FACC*‡ Baltimore, Maryland; and Burlington, Vermont Objectives This study sought to investigate the relationship between C-reactive protein (CRP) and regional left ventricular (LV) function in asymptomatic individuals without a history of cardiovascular disease. Background C-reactive protein is associated with an increased risk for developing cardiovascular disease. However, the relationship between CRP and subclinical LV dysfunction has not been evaluated in asymptomatic individuals. Methods Regional myocardial function was analyzed as peak systolic circumferential shortening strain (Ecc) using the harmonic-phase method by tagged magnetic resonance imaging in 1,164 individuals without symptomatic cardiovascular disease from the MESA (Multi-Ethnic Study of Atherosclerosis) trial (age 66.4 ⫾ 9.6 years old). Regions were defined by coronary territories: left anterior descending artery (LAD), left circumflex artery (LCX), and right coronary artery (RCA). The relationship between log-CRP concentration and Ecc was studied by multivariable linear regression after adjustment for demographic characteristics, risk factors, and therapy (including hormone replacement therapy). Results For each region, associations differed by gender with no association of CRP and regional LV function among women. In men, after adjustment, higher log-CRP was significantly associated with lower (absolute) Ecc in the LAD and RCA regions (regression coefficient 0.37 per unit higher log-CRP [95% confidence interval [CI] 0.08 to 0.65] and 0.31 [95% CI 0.02 to 0.59], respectively) and peak systolic Ecc overall (regression coefficient 0.32 [95% CI 0.05 to 0.58]). In the LCX region, the association was weaker (p ⫽ 0.06). Conclusions Among individuals without evident heart failure or other cardiovascular disorders, higher CRP was associated with lower systolic myocardial function in all regions in men but not in women. These findings support the role of inflammation and atherosclerosis in incipient myocardial dysfunction. (Multi-Ethnic Study of Atherosclerosis; http://clinicaltrials.gov/ct/show/NCT00005487). (J Am Coll Cardiol 2007;49:594–600) © 2007 by the American College of Cardiology Foundation Inflammation plays an important role in the development and progression of atherosclerosis and congestive heart failure (CHF) (1). The inflammatory process contributes to the formation of early atherosclerotic plaques in the form of lipid-laden macrophages and induces plaque weakening and rupture leading to acute coronary syndromes and sudden death (2,3). Furthermore, many circulating markers of inflammation, particularly C-reactive protein (CRP), are associated with increased morbidity and mortality in asymptomatic individuals and in patients with cardiovascular disease and CHF (4 –9). Coronary artery disease (CAD) is the major cause of left ventricular (LV) dysfunction and CHF (10). In this regard, traditional risk factors for CAD as well as CRP are predictors of CHF. Indeed, in the Health ABC (Health, Aging, and Body Composition) study, among all major *From the Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Maryland; †Departments of Medicine and Pathology, University of Vermont, Burlington, Vermont; ‡Radiology Department, Johns Hopkins Medical Institutions, Baltimore, Maryland; and §Department of Epidemiology, Bloomberg School of Public Health and Hygiene, Johns Hopkins University, Baltimore, Maryland. This study was supported by the National Heart, Lung, and Blood Institute grant (RO1-HL66075-01) and the Multi-Ethnic Study of Athero- sclerosis study contracts (NO1-HC-95162, NO1-HC-95168, and NO1-HC95169). Dr. Lima is also supported by the Johns Hopkins Reynolds Center, and Dr. Rosen is supported by the Israeli Heart Society and the Organization of American Physician Fellowship for Medicine in Israel. Peter Libby, MD, acted as Guest Editor for this article. Manuscript received May 16, 2006; revised manuscript received September 8, 2006, accepted September 28, 2006. JACC Vol. 49, No. 5, 2007 February 6, 2007:594–600 cardiovascular events, CRP was most strongly associated with future CHF (11). Because CAD is regional, it is intuitive to expect that the progressive LV dysfunctional process that underlies CHF would commence as a regional process that eventually results in global dysfunction and failure. In this regard, although most studies relating inflammatory markers to the development of CAD used clinical events as end points, none have yet examined the relationship between systemic markers of inflammation and regional LV dysfunction in asymptomatic individuals. The goal of this study was to investigate the association between CRP and the presence and extent of regional LV dysfunction in asymptomatic participants of the MESA (Multi-Ethnic Study of Atherosclerosis) trial. Our hypothesis was that higher levels of CRP would be related to regional LV dysfunction involving 1 or more coronary territories independently of traditional risk factors. Methods The MESA trial is a prospective study designed to evaluate mechanisms underlying the development and progression of subclinical cardiovascular disease in asymptomatic individuals (12). There were 6,814 men and women, 45 to 85 years of age, from 4 ethnicities (non-Hispanic white, African American, Hispanic, and Chinese) enrolled at 6 field centers (Winston Salem, North Carolina; New York, New York; Baltimore, Maryland; Minneapolis, Minnesota; Chicago, Illinois; and Los Angeles, California). At entry, all participants underwent extensive evaluation including clinical history, physical examination, and laboratory tests including fasting glucose, lipid panel, and CRP. The MESA protocol was approved by the institutional review boards in all participating centers. Informed consent was obtained from all study participants. Tagged MRI studies. In an ancillary study of MESA, 1,184 participants randomly selected underwent tagged magnetic resonance imaging (MRI) studies at enrollment (from September 2001 to September 2002) in 6 centers. Images were acquired by whole-body scanners (1.5 CVi, General Electric Medical Systems, Waukesha, Wisconsin, and Sonata/Symphony Siemens Medical Solutions, Erlangen, Germany) using electrocardiograph-triggered segmented k-space fast spoiled gradient-echo pulse sequence during breath holds. After completing the standard protocol, 3 tagged short-axis slices (base to apex) were obtained. Parallel striped tags were prescribed in 2 orthogonal orientations (0° and 90°) using electrocardiograph-triggered fast gradient echo sequence with spatial modulation of magnetization. Parameters for tagged images were: field of view 40 cm; slice thickness 7 to 8 mm; repetition time 6 ms; echo time 3.0 ms; flip angle 10° to 12°; phase encoding views 128 with 6 phase encoding views per segment; temporal resolution 40 ms; tag spacing 7 mm. Rosen et al. Association Between CRP and LV Function 595 The LV mass was determined Abbreviations and Acronyms for each participant using dedicated commercially available CAD ⴝ coronary artery software (MASS, version 4.2, disease Medis, Leiden, the Netherlands) CHF ⴝ congestive heart at end diastole. failure Strain analysis. Short-axis CI ⴝ confidence interval tagged slices were analyzed using CRP ⴝ C-reactive protein HARP (harmonic phase). The Ecc ⴝ circumferential strain HARP program (Diagnosoft, IQR ⴝ interquartile range Palo Alto, California) enables a LAD ⴝ left anterior fast determination of myocardial descending artery strain (13–15). In the present LCX ⴝ left circumflex artery study, peak systolic midwall cirLV ⴝ left ventricular cumferential strain (Ecc) was deMESA ⴝ Multi-Ethnic Study termined in 12 segments in 3 of Atherosclerosis slices. By convention, systolic RCA ⴝ right coronary artery Ecc is normally negative because of circumferential shortening, and reduced (absolute) Ecc values reflect decreased regional function (for example, Ecc ⫽ ⫺12% reflects lower regional function when compared with Ecc ⫽ ⫺18%). Regional strains were analyzed according to coronary perfusion areas (left anterior descending artery [LAD], left circumflex artery [LCX], and right coronary artery [RCA] territories). Assignment to coronary territories was done according to published standards (16). Peak global systolic strain was defined as the peak midwall Ecc averaged across all midwall segments. Risk factors and CRP concentrations. Hypertension was defined as diastolic blood pressure ⱖ90 mm Hg, systolic blood pressure ⱖ140 mm Hg, or receiving treatment for hypertension. High-normal diastolic blood pressure was defined as ⬍90 and ⱖ85 mm Hg. Dyslipidemia was defined as total cholesterol ⱖ240 mg/dl, low-density lipoprotein cholesterol ⱖ160 mg/dl, triglycerides ⱖ150 mg/dl, highdensity lipoprotein cholesterol ⬍45 mg/dl, or receiving treatment for hyperlipidemia. Diabetic individuals were defined as either having fasting plasma glucose ⱖ126 mg/dl or receiving treatment for diabetes. Impaired fasting glucose was defined as glucose ⱖ100 and ⬍126 mg/dl. Smoking status was defined as current smoking, former smoking, or never smoked. C-reactive protein was measured using the BNII nephelometer (N High-Sensitivity CRP; Dade Behring, Deerfield, Illinois). Analytical intra-assay coefficients of variation (CVs) range from 2.3% to 4.4%, and interassay CVs range from 2.1% to 5.7%. Statistical analysis. The distribution of CRP was skewed; therefore, log-transformation was performed. Data for CRP are presented as median and interquartile range (IQR). All analyses were done using STATA-8 software (Stata Corp., College Station, Texas). The CRP levels in different subgroups were compared using the Mann-Whitney U and Kruskal-Wallis tests. Linear regression was used to study the relationship between log-CRP and regional Ecc. To test whether the 596 Rosen et al. Association Between CRP and LV Function JACC Vol. 49, No. 5, 2007 February 6, 2007:594–600 relationship between regional LV function and CRP differed by gender, age, ethnicity, or central obesity indexed by waist circumference, interaction terms between CRP and these factors were included in the initial multivariable regression models. Only the gender ⫻ log-CRP interaction was significant in most of the regions (p values for interactions were 0.1, 0.07, 0.03, and 0.04 for Ecc in the LAD, LCX, RCA, and peak global Ecc, respectively). Therefore, men and women were analyzed separately. Multivariable linear regression was used to study the independence of the association of log-CRP with regional Ecc. Variables included as potential confounders were age, ethnicity, waist circumference, hypertension, total cholesterol, treatment for hypertension or high cholesterol, diabetes mellitus, and smoking status. In women, hormone replacement therapy use was also included (current use vs. former and never use). Regression was performed in 3 steps. Model I (demographic parameters) included age, ethnicity, and waist circumference. Model II (risk factors): history of hypertension, antihypertensive medication, cholesterol, antihyperlipidemic medication, smoking status, and history of diabetes mellitus in addition to the variables included in Model I. In women, adjustment for hormone replacement therapy status (current users vs. nonusers) was added. Model III included demographic parameters (I), risk factors (II), and LV mass or coronary artery calcium scores in the corresponding arteries (e.g., coronary artery calcium scores in the LAD for Ecc LAD). Statistical significance was defined as p ⬍ 0.05. Results Risk factor profiles of the study participants are shown in Table 1. A total of 1,184 individuals underwent tagged Risk Factor Profile of the Study Participants Table 1 Risk Factor Profile of the Study Participants Men Women Gender Difference (p Value*) Characteristics Number 635 (54) 549 (46) 191 (30) 173 (30) Ethnicity Caucasian Asian 70 (11) 65 (12) African American 169 (27) 153 (28) Hispanic 205 (32) 158 (29) 0.6 66 ⫾ 10 67 ⫾ 9 0.6 27.2 ⫾ 3.9 28.3 ⫾ 5.2 ⬍0.001 SBP (mm Hg) 128 ⫾ 19 130 ⫾ 23 0.1 DBP (mm Hg) 75 ⫾ 9 69 ⫾ 11 ⬍0.001 Age (yrs) Body mass index (kg/m2) Risk factors Blood pressure Hypertensive 265 (41.7) 261 (47.5) 0.05 Treatment for HTN 208 (32.8) 190 (34.6) 0.5 Lipids Total cholesterol (mg/dl) 186 ⫾ 33 202 ⫾ 36 LDL cholesterol (mg/dl) 116 ⫾ 30 120 ⫾ 30 0.02 HDL cholesterol (mg/dl) 46 ⫾ 12 56 ⫾ 15 ⬍0.001 Triglycerides (mg/dl) 130 ⫾ 84 132 ⫾ 77 ⬍0.001 0.6 Dyslipidemia 248 (39) 197 (36) 0.3 Treatment for hyperlipidemia 118 (19) 116 (21) 0.3 Never smoked 268 (42) 338 (62) Former smoker 282 (45) 159 (29) Current smoker 82 (13) 48 (9) ⬍0.001 ⬍0.001 Smoking Glucose Plasma glucose (mg/dl) 110 ⫾ 31 103 ⫾ 21 Diabetes mellitus 76 (12) 58 (11) CRP (mg/l)† 1.3 (0.7–3.0) 2.6 (1.2–5.7) ⬍0.001 LV mass (g) 166 ⫾ 39 122 ⫾ 27 ⬍0.001 0.4 Percentages are shown in parentheses. Continuous variables are presented as mean ⫾ standard deviation. *The p values were calculated by t test for continuous variables and chi-square for categorical variables; †because of the skewed distribution of CRP, median values and interquartile ranges are presented. Mann-Whitney U test was used to compare CRP levels. To convert values for total, HDL, and LDL cholesterol to millimoles per liter, multiply by 0.0259; to convert values for glucose to millimoles per liter, multiply by 0.0555; to convert values for triglycerides to millimoles per liter, multiply by 0.0113. CRP ⫽ C-reactive protein; DBP ⫽ diastolic blood pressure; HDL ⫽ high-density lipoprotein; HTN ⫽ hypertension; LDL ⫽ low-density lipoprotein; LV mass ⫽ left ventricular mass; SBP ⫽ systolic blood pressure. Rosen et al. Association Between CRP and LV Function JACC Vol. 49, No. 5, 2007 February 6, 2007:594–600 MRI, of whom there were 1,164 (98.3%) participants with available CRP data. Their mean age was 66.4 ⫾ 10 years. Compared with the overall MESA trial cohort (total 6,814 participants), the studied subgroup included a higher percentage of men (54% vs. 47%, p ⬍ 0.001), a greater number of Caucasians, and a smaller number of Hispanic individuals (p ⬍ 0.001 for both ethnic groups). However, the distributions of risk factors and CRP concentrations did not differ from the overall MESA trial cohort. Men had a higher diastolic blood pressure and LV mass compared with women, and were more likely to be current or former smokers. Women had a higher body mass index and higher cholesterol levels (total, low-density lipoprotein, and highdensity lipoprotein cholesterol) than men. CRP and participant characteristics. Median CRP concentrations in men were 1.3 mg/l (IQR 0.7 to 3.0 mg/l), and in women 2.6 mg/l (IQR 1.2 to 5.7 mg/l, p ⬍ 0.001). Among women but not men, CRP was significantly lower among those receiving lipid-lowering therapy compared with nonusers (2.1 mg/l [IQR 0.6 to 3.0 mg/l] vs. 2.7 mg/l [IQR 1.3 to 5.9 mg/l], p ⫽ 0.02). A total of 27% of the women included in the cohort were current users of hormone replacement therapy. Women who were currently using hormone replacement therapy had significantly higher CRP levels compared with former or never-treated women (3.5 mg/l [IQR 1.8 to 6.7 mg/l] vs. 2.3 mg/l [IQR 1.1 to 4.9 mg/l], p ⫽ 0.0004). In both genders, current cigarette smokers had higher CRP levels than former smokers or persons who had never smoked (p ⫽ 0.001). Finally, there was a positive relationship between LV mass and log-CRP in women (regression coefficient 4.5 g LV mass per 1 unit higher log-CRP [mg/l], 95% confidence interval [CI] 2.4 to 6.5, p ⬍ 0.001) and in men (regression coefficient 5.0 g LV mass per 1 unit higher log-CRP [mg/l], 95% CI 2.0 to 8.0, p ⫽ 0.001). This relationship remained significant after multivariate adjustment for demographic characteristics and risk factors. Relationships between log-CRP and regional LV function. Because of a significant gender interaction, results are shown separately for men and women. The unadjusted associations of CRP and regional LV function for men and women are shown in Figure 1. In addition, these relationships are shown as regression coefficients in Table 2. A positive regression coefficient indicates an association between higher log-CRP and lower absolute Ecc values, i.e., reduced regional LV function. Higher log-CRP was associated with lower regional LV function in all regions in men but not in women (Fig. 1, Table 2). In men, after adjustment for age, ethnicity, and traditional risk factors, the relationship between log-CRP and lower regional LV function was attenuated slightly for different regions (Table 3, models I and II). Similar results were seen when waist circumference was substituted by body mass index in the regression model. However, after further adjustment for LV mass, the relationship between log-CRP and Ecc weakened and remained statistically significant only Figure 1 597 Peak Regional Systolic Ecc (%) by CRP Quartiles (mg/l) in Men and Women (A) Mean ⫹ SE error bars of peak systolic circumferential strain (Ecc) in the left anterior descending artery (LAD), left circumflex artery (LCX), and right coronary artery (RCA) regions are shown. Open bars, dotted bars, ruled bars, and solid bars indicate 1st, 2nd, 3rd, and 4th quartiles of C-reactive protein (CRP) levels, respectively. (B) Simple linear regression was used to determine the trend. The p values indicate significance levels. By convention, systolic Ecc is normally negative because of circumferential shortening. Therefore, lower (absolute) values of Ecc reflect decreased regional function. in the LAD territory (Table 3, model III). In contrast, the results were not markedly changed after adjusting for coronary calcium scores in the corresponding regions (data not shown). In women, in addition to the other covariates, hormone replacement therapy use was added to the regression model. However, no associations between log-CRP and regional Ecc values were observed (Table 3). Results remained unchanged after including LV mass in the regression model. Discussion The main finding of this study is that higher CRP concentration is related to lower regional LV function determined by Ecc in men, but not in women without evident heart failure or CAD in the MESA trial. This association was only modestly attenuated with adjustment for demographic parameters and risk factors. Additional adjustment for LV mass measured by MRI weakened this relationship. Rosen et al. Association Between CRP and LV Function 598 JACC Vol. 49, No. 5, 2007 February 6, 2007:594–600 Relationship Between Regional Ecc and Log-CRP in Men and Women Table 2 Relationship Between Regional Ecc and Log-CRP in Men and Women Men Region Women Regression Coefficient 95% CI p Value Regression Coefficient LAD 0.45 0.17–0.72 0.002 0.09 ⫺0.27–0.44 95% CI p Value 0.6 LCX 0.39 0.08–0.71 0.014 ⫺0.08 ⫺0.5–0.34 0.7 RCA 0.35 0.06–0.63 0.016 ⫺0.13 ⫺0.47–0.21 0.5 Global Ecc 0.38 0.13–0.63 0.003 ⫺0.06 ⫺0.40–0.27 0.7 Relationship is expressed as a regression coefficient (unadjusted). Regression coefficients are the differences in Ecc (%) per 1 U higher log-CRP (mg/l). A positive value indicates an association of higher CRP with decreased LV function. The p values indicate the significance levels of the regression coefficients for changes in regional strain for each gender. CI ⫽ confidence interval; CRP ⫽ C-reactive protein; Ecc ⫽ circumferential strain; LAD ⫽ left anterior descending artery; LCX ⫽ left circumflex artery; LV ⫽ left ventricular; RCA ⫽ right coronary artery. Inflammatory markers including CRP are associated with an increased risk for cardiovascular morbidity and mortality in asymptomatic men and women, and in patients with acute coronary syndromes (1,4 – 6,8,17,18). Furthermore, in the Health ABC study, among major cardiovascular events, CRP was most closely correlated with risk of future CHF (11). Our findings document the association between CRP and LV dysfunction among subjects without clinical heart failure or coronary disease. In contrast to our study, gender interactions were not observed in previous studies of clinical outcomes. We hypothesize that the presence of subclinical atherosclerosis, endothelial dysfunction, and LV hypertrophy might underlie the association between CRP and regional LV dysfunction. These mechanisms are probably not mutually exclusive, and each may contribute substantially to the relationship between CRP and regional LV dysfunction. Inflammation plays an important role in the development and progression of atherosclerosis. In the early stages of atherogenesis, local inflammatory stimuli including oxidized low-density lipoprotein lead to cytokine production (1,2,19). These cytokines in turn induce endothelial adhesion and migration of monocytes into the lesion area, producing early atherosclerotic lesions. The CRP seems to play a role in this process by facilitating the activation of inflammatory cells and enhancing cytokine production. Furthermore, the inflammatory process is associated with plaque weakening, rupture, and thrombus formation (1– 4). Thus, it is logical to think that the relationship between CRP and regional LV dysfunction may be related to the association of CRP with these inflammatory processes known to promote local atherosclerosis. In this regard, it is important to mention that the relationship between CRP and regional LV function was not modulated by coronary calcium score. This process may or not be associated with small regions of myocardial infarction or scar tissue, even in the absence of epicardial CAD, possibly because of local thrombosis or embolism. These areas can be detected using delayed contrast hyperenhancement (20,21). Indeed, scars indicative of unrecognized myocardial infarctions have been detected by delayed hyperenhancement in a considerable number (20%) of elderly individuals participating in a communitybased study in Sweden (22). Unfortunately, this technique has not been used in the MESA trial, and this plausible explanation could not be studied. Additionally, CRP may be related to incipient myocardial dysfunction through its well-established association with Relationship Demographic Parameters; Between Regional Parameters Ecc and and Log-CRP Risk Factors; in Men and and Demographic in Women After Parameters, Adjustment Risk for Factors, Demographic and LV Mass Relationship Between Regional Ecc and Log-CRP in Men and in Women After Adjustment for Demographic Table 3 Parameters; Demographic Parameters and Risk Factors; and Demographic Parameters, Risk Factors, and LV Mass I Region Regression Coefficient II III p Value Regression Coefficient p Value Regression Coefficient p Value Men LAD 0.44 (0.15–0.72) 0.002 0.37 (0.08–0.65) 0.01 0.31 (0.01–0.61) 0.04 LCX 0.37 (0.05–0.69) 0.022 0.32 (⫺0.01–0.64) 0.06 0.32 (⫺0.03–0.66) 0.07 RCA 0.34 (0.05–0.62) 0.020 0.31 (0.02–0.59) 0.04 0.18 (⫺0.12–0.49) 0.23 Global Ecc 0.37 (0.12–0.63) 0.004 0.32 (0.05–0.58) 0.02 0.26 (0.01–0.53) 0.06 Women LAD 0.10 (⫺0.25–0.46) 0.57 0.16 (⫺0.44–0.76) 0.60 0.24 (⫺0.36–0.86) 0.42 LCX ⫺0.05 (⫺0.48–0.37) 0.80 ⫺0.20 (⫺0.90–0.49) 0.57 ⫺0.20 (⫺0.92–0.52) 0.59 RCA ⫺0.13 (⫺0.48–0.21) 0.45 ⫺0.20 (⫺0.77–0.36) 0.49 ⫺0.27 (⫺0.85–0.31) 0.36 Global Ecc ⫺0.04 (⫺0.38–0.30) 0.80 ⫺0.09 (⫺0.65–0.48) 0.76 ⫺0.06 (⫺0.64–0.52) 0.84 Regression coefficients are the differences in Ecc (%) per 1-U higher log-CRP (mg/l). A positive value indicates an association of higher CRP with LV dysfunction. The numbers in parentheses indicate 95% confidence intervals. The p values indicate significance levels of the regression coefficients for changes in regional strains. Demographic parameters (model I) include age, ethnicity, and waist circumference. Risk factors (model II) include history of hypertension, antihypertensive medication, cholesterol, antihyperlipidemic medication, smoking status, and history of diabetes mellitus. In women, adjustment for hormone replacement therapy status (current users vs. nonusers) was also included. Model III includes demographic parameters (I), risk factors (II), and LV mass. Abbreviations as in Table 2. JACC Vol. 49, No. 5, 2007 February 6, 2007:594–600 endothelial dysfunction. The CRP may directly alter endothelial function by reducing local production of nitric oxide, or indirectly by increasing levels of reactive oxygen species, thus reducing endothelial induced vasodilation (2,23–26). A third possible mechanism pertains to the association between CRP and LV mass. We observed a significant association between CRP and LV mass. This relationship has been shown previously in patients with hypertension and renal failure (27,28). It has been previously shown that concentric LV hypertrophy is related to decreased myocardial function (29 –32). In the current study, after adjustment for LV mass, the association of higher CRP concentrations and reduced myocardial strain (Ecc) was attenuated, suggesting that the relationship between CRP and regional LV function might be linked to the association between CRP and LV mass. An unexpected finding of this study was the gender difference in the association of CRP and regional LV dysfunction. In men but not women, higher CRP was significantly associated with regional LV dysfunction. Substantial gender differences in the presence of risk factors, shown in Table 1, may partly explain this difference, but the gender difference remained after controlling for those variables. It is theoretically possible, but unlikely, that women with elevated CRP and reduced regional LV function developed symptoms earlier than men, and were therefore excluded from the MESA trial. A third and more plausible explanation is that gender-specific differences in the association between CRP and regional LV function are modulated through gender-related differences in LV mass. Previous studies have described gender-specific differences in LV remodeling and the development of LV dysfunction and CHF (33–38). The association between CRP levels and LV mass and the gender-specific differences in the CRP/ regional dysfunction relationship fit this finding of gender differences in the cardiac remodeling process. In contrast, the Cardiovascular Health Study and the Health ABC investigators reported a significant association between higher CRP levels and the incidence of CHF in both genders (11,39). These discrepancies suggest that in older individuals, gender-related differences in the CRP LV dysfunction relationships might disappear as women catch up with men in the degree of atherosclerosis and inflammation. However, this possibility should be further explored. Finally, the finding of regional differences in the association between CRP and Ecc is noteworthy. The relationship between CRP and regional function in the LAD and RCA seems to be stronger than in the LCX territory. This may be attributable to statistical power, because the variation in the LCX has been found to be slightly greater than in other regions, probably because of a decreased signal-tonoise ratio in the posterior wall. In addition, in a different study, we have shown a greater coronary artery calcium score and a higher extent of significant CAD in the LAD region compared with other regions (unpublished data). Further studies should be performed to clarify these findings. Rosen et al. Association Between CRP and LV Function 599 Methodological considerations. Our study includes 1,164 subjects, making this one of the largest MRI studies of quantitative regional myocardial function that we are aware of. The HARP software is a robust analytical tool that allows for efficient and reliable determinations of regional LV function by MRI tagging (13,15). Aside from its size, the MESA trial entails a heterogeneous population from different ethnicities. On the other hand, the cross-sectional study design impairs the ability to establish the temporal nature of the association. Participants were selected to participate in the MESA trial through a population-based process designed to minimize biases typically associated with studies of volunteers. However, they may not represent a random sample of the population. In addition, excluding symptomatic patients could have affected the results of this study, as discussed earlier. Temporal resolution is an important determinant of the quality of strain measurement. In the present study, the mean temporal resolution was 40 ms. This temporal resolution is lower than the resolution that can be achieved by echocardiography (i.e., 7 to 10 ms). However, MRI is not limited by acoustic windows and scanning angles and can provide a detailed strain map of the entire myocardium. In addition, a previous study has shown a high correlation between strain values measured by echocardiography and tagged MRI (40). Finally, except for a small study that measured only for regional myocardial perfusion, contrast-enhanced MR images were not acquired routinely in the MESA trial. Therefore, we could not address the possibility that areas with reduced regional function may indeed reflect silent infracted regions manifesting as a delayed enhancement pattern. In conclusion, we document an inverse relationship between CRP levels and regional LV function in men. This association was seen in all regions and did not change after adjusting for age, traditional risk factors, or medical treatment. In contrast, such a relationship was not evident in women. The association between CRP and LV function was attenuated by adjustment for LV mass. Further studies are warranted to elucidate the interrelationship between inflammation, LV mass, and gender in the development of LV dysfunction and heart failure. Acknowledgments The authors thank the participants of the MESA trial and the entire community of MESA investigators and staff for their support and valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. Reprint requests and correspondence: Dr. João A. C. Lima, Cardiology Division, Blalock 524, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, Maryland 21287-0409. E-mail: [email protected]. 600 Rosen et al. Association Between CRP and LV Function REFERENCES 1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–26. 2. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109:II2–10. 3. Yeh ET. CRP as a mediator of disease. Circulation 2004;109:II11– 4. 4. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003;169:203–14. 5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836 – 43. 6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9. 7. Ridker PM. Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic disease. Eur Heart J 1998;19:1119 –21. 8. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731–3. 9. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112:1428 –34. 10. Packer M. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A–38A. 11. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317–22. 12. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002;156: 871– 81. 13. Garot J, Bluemke DA, Osman NF, et al. Fast determination of regional myocardial strain fields from tagged cardiac images using harmonic phase MRI. Circulation 2000;101:981– 8. 14. O’Dell WG, McCulloch AD. Imaging three-dimensional cardiac function. Annu Rev Biomed Eng 2000;2:431–56. 15. Osman NF, Prince JL. Visualizing myocardial function using HARP MRI. Phys Med Biol 2000;45:1665– 82. 16. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539 – 42. 17. Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J 1998;19:1–3. 18. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999;10 Suppl 1: S9 –12. 19. Verma S, Szmitko PE, Yeh ET. C-reactive protein: structure affects function. Circulation 2004;109:1914 –7. 20. Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation 1995;92: 1117–25. 21. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992–2002. 22. Ebeling BC, Bjerner T, Johansson L, Lind L, Ahlstrom H. Myocardial scars more frequent than expected magnetic resonance imaging detects potential risk group. J Am Coll Cardiol 2006;48:765–71. 23. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058 – 67. JACC Vol. 49, No. 5, 2007 February 6, 2007:594–600 24. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102: 2165– 8. 25. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109:II27–33. 26. Harrison DG, Cai H. Endothelial control of vasomotion and nitric oxide production. Cardiol Clin 2003;21:289 –302. 27. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:2116 –23. 28. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 2003;84:S88 –93. 29. Palmon LC, Reichek N, Yeon SB, et al. Intramural myocardial shortening in hypertensive left ventricular hypertrophy with normal pump function. Circulation 1994;89:122–31. 30. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996;93:259 – 65. 31. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995;26:195–202. 32. Rosen BD, Edvardsen T, Lai S, et al. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multi-Ethnic Study of Atherosclerosis. Circulation 2005;112:984 –91. 33. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 2002; 8:101–7. 34. Weinberg EO, Thienelt CD, Katz SE, et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999;34:264 –73. 35. Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 1999;33: 676 – 80. 36. Rosen BD, Edvardsen T, Lai S, et al. Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the Multi-Ethnic Study of Atherosclerosis. Circulation 2005;112:984 –91. 37. Salton CJ, Chuang ML, O’Donnell CJ, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol 2002;39: 1055– 60. 38. Hees PS, Fleg JL, Lakatta EG, Shapiro EP. Left ventricular remodeling with age in normal men versus women: novel insights using three-dimensional magnetic resonance imaging. Am J Cardiol 2002; 90:1231– 6. 39. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000;35:1628 –37. 40. Edvardsen T, Gerber BL, Garot J, Bluemke DA, Lima JA, Smiseth OA. Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: validation against three-dimensional tagged magnetic resonance imaging. Circulation 2002;106:50 – 6. APPENDIX For a list of multivariate regression models, please see the online version of this article.